Dr. Kim on the Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

Edward S. Kim, MD, MBA, physician-in-chief at City of Hope Orange County and vice physician-in-Chief at City of Hope National Medical Center, discusses the importance of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-mutated non–small cell lung cancer (NSCLC).

The phase 2 DESTINY-Lung01 trial (NCT03505710) evaluated trastuzumab deruxtecan in patients with HER2-overexpressed or HER2-mutated advanced NSCLC.

Based on the progression-free survival rates achieved by trastuzumab deruxtecan in this patient population, it could serve as another potential treatment option, Kim explains. The overall goal is to identify patients with HER2 biomarkers and have agents that will target them safely and effectively, Kim adds. HER2-targeted antibody-drug conjugates are opening up another treatment area for patients, Kim says.

Trastuzumab deruxtecan was evaluated in patients who were previously treated, Kim continues. However, it is hoped that genomic testing can reveal biomarkers such as HER2 that can help move tailored targeted therapy into earlier lines of treatment, Kim concludes.

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive(R).